Teva Pharmaceutical Indus Market Sentiment

SPY770.73+0.22%QQQ722.85+0.73%BTC/USD82,673.44−0.32%DIA524.31−0.01%GLD377.24−0.11%TLT79.93−0.25%

Premium

Teva Pharmaceutical Industries Ltd

TEVANYSE

Trade with Public

$40.85

-0.46-1.11%

Last update: Oct 20, 7:35 PM

$41.14

-0.17-0.41%

Overview News Earnings Forecast Events Price Targets FinancialsSentimentOwnership Compare Options Stock Report

Earnings: Q3 2026 Earnings in 14 days from now on Tue Nov 3rd, before the market open

Teva Pharmaceutical Indus Market Sentiment - Benzinga

Teva Pharmaceutical Indus Market Sentiment

Market sentiment signals for Teva Pharmaceutical Indus (TEVA): analyst consensus, short interest, options flow and insider activity.

Key Signals

Analyst Consensus▲ Buy

Short Interest▲ 2.6% short float

Options Flow▲ 0.83 P/C ratio

Insider Activity▼ Net Seller (30d)

Analyst Consensus

Buy

15 analysts

Options Flow (P/C)

0.83

More calls — Bullish

7,826 calls · 6,488 puts

Avg Consensus PT

$40

-2.6%

Highest Price Target

$55

+33.7%

TD Cowen

Lowest Price Target

$11

-73.3%

Goldman Sachs

Short Interest

2.6%

Declining — Bullish

Insider Activity (30d)

Net Seller

Short Interest — % of Float

Recent Analyst Actions

Date	Firm	Analyst & Accuracy	Upside / Downside	PT Change	Action	Rating
Oct 15, 2026	Barclays	Glen Santangelo—	+14.2%	$42 → $47	Maintained	Overweight
Oct 12, 2026	JP Morgan	Chris Schott—	+21.5%	$40 → $50	Maintained	Overweight
Oct 1, 2026	TD Cowen	Joseph Thome—	+33.7%	$55	Initiate	Buy
Sep 23, 2026	Oppenheimer	Les Sulewski—	+21.5%	$50	Initiate	Outperform
Sep 9, 2026	Leerink Partners	Daniel Clark—	+9.4%	$45	Initiate	Outperform
Sep 4, 2026	UBS	Ashwani Verma—	+16.7%	$42 → $48	Maintained	Buy
Aug 12, 2026	Barclays	Glen Santangelo—	+2.1%	$40 → $42	Maintained	Overweight
Jul 28, 2026	Piper Sandler	David Amsellem—	+7.0%	$42 → $44	Maintained	Overweight
May 6, 2026	Barclays	Glen Santangelo—	-2.8%	$38 → $40	Maintained	Overweight
Apr 30, 2026	Truist Securities	Les Sulewski—	+9.4%	$42 → $45	Maintained	Buy
Apr 30, 2026	Piper Sandler	David Amsellem—	+2.1%	$41 → $42	Maintained	Overweight
Apr 30, 2026	UBS	Ashwani Verma—	+2.1%	$36 → $42	Maintained	Buy
Apr 30, 2026	JP Morgan	Chris Schott—	-2.8%	$35 → $40	Maintained	Overweight
Apr 9, 2026	B of A Securities	Jason Gerberry—	+2.1%	$38 → $42	Maintained	Buy
Mar 4, 2026	Piper Sandler	David Amsellem—	-0.3%	$40 → $41	Maintained	Overweight
Feb 18, 2026	Truist Securities	Les Sulewski—	+2.1%	$38 → $42	Maintained	Buy
Feb 9, 2026	Goldman Sachs	Matt Dellatorre—	+9.4%	$36 → $45	Maintained	Buy
Jan 30, 2026	Barclays	Glen Santangelo—	-7.6%	$35 → $38	Maintained	Overweight
Jan 29, 2026	Truist Securities	Les Sulewski—	-7.6%	$36 → $38	Maintained	Buy
Jan 29, 2026	Scotiabank	Louise Chen—	-2.8%	$35 → $40	Maintained	Sector Outperform
Jan 6, 2026	Jefferies	Glen Santangelo—	-2.8%	$29 → $40	Maintained	Buy
Dec 22, 2025	Piper Sandler	David Amsellem—	-2.8%	$30 → $40	Maintained	Overweight
Dec 19, 2025	Goldman Sachs	Matt Dellatorre—	-14.9%	$31 → $35	Maintained	Buy
Dec 16, 2025	JP Morgan	Chris Schott—	-14.9%	$28 → $35	Maintained	Overweight
Dec 9, 2025	Barclays	Glen Santangelo—	-14.9%	$35	Initiate	Overweight